Intuitive Surgical announces FDA clearance of da Vinci Sp Surgical System Intuitive Surgical announced it has received FDA 510(k) clearance for the da Vinci Sp Surgical System, which is designed to expand the company's single-incision product offering. This initial clearance is specific to urologic surgical procedures that are appropriate for a single port approach. The company does not intend to commercialize the da Vinci Sp technology until the current technology is engineered to be fully compatible with the newly released da Vinci Xi Surgical System, currently projected for the second half of 2015. This will require product refinements, supply chain optimization and additional regulatory clearances.
Intuitive Surgical initiated with an Overweight, $575 target at Barclays Barclays analyst Matthew Taylor started shares of Intuitive Surgical with an Overweight rating and $575 price target. Taylor thinks surgery share will continue to shift to robotic and believes demand for Intuitive's da Vinci among general surgeons is very high. The stock closed yesterday down $4.17 to $492.45.